Prelude Therapeutics Incorporated (PRLD) Financials

PRLD Assets vs Liabilities

DateAssetsLiabilities
June 30, 2026 189.4 million 55.6 million
March 31, 2026 119.6 million 59.5 million
Dec. 31, 2025 141.3 million 72.7 million
Sept. 30, 2025 94.8 million 36.2 million

PRLD Free Cash Flow and Stock based compensation

Graph available only for paid members. Upgrade to see it.
DateFree Cash FlowStock based compensation
June 30, 2026 -15.6 million 2.0 million
March 31, 2026 -21.7 million 2.0 million
Dec. 31, 2025 23.1 million 1.8 million
Sept. 30, 2025 -19.1 million 2.4 million

PRLD Net Income

No data available :(

PRLD Cash and Debt

Graph available only for paid members. Upgrade to see it.
DateCashDebtCapital Lease
June 30, 2026 151.8 million 14.9 million 14.9 million
March 31, 2026 81.6 million - 17.7 million
Dec. 31, 2025 103.2 million - 17.8 million
Sept. 30, 2025 55.0 million - 17.9 million

PRLD Shares Outstanding

Graph available only for paid members. Upgrade to see it.
DateShares Outstanding
June 30, 2026 98.4 million
March 31, 2026 82.5 million
Dec. 31, 2025 63.0 million
Sept. 30, 2025 76.1 million

PRLD Expenses

Graph available only for paid members. Upgrade to see it.
DateCapexR&DG&AS&M
June 30, 2026 - 16.1 million 5.0 million -
March 31, 2026 - 13.6 million 4.8 million -391000
Dec. 31, 2025 - 18.0 million 5.0 million -
Sept. 30, 2025 - 21.7 million 5.2 million -

PRLD Cost of Revenue

Graph available only for paid members. Upgrade to see it.
DateRevenueCost of Revenue
June 30, 2026 5.7 million -
March 31, 2026 4.6 million 391000
Dec. 31, 2025 5.6 million 418000
Sept. 30, 2025 6.5 million 425000

PRLD

Price: $5.63

52 week price:
0.75
5.91

Earnings Per Share: -0.73 USD

Exchange: NMS

Sector: Healthcare

Industry: Biotechnology

Country: United States

Volume: 65500

Market Capitalization: 442.9 million

Links: